Tech Company Financing Transactions
Verismo Therapeutics Funding Round
On 7/18/2023, Verismo Therapeutics landed $17 million in Series A funding from Dongkoo Bio&Pharma and Hong Leong Bank.
Transaction Overview
Company Name
Announced On
7/18/2023
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
Dongkoo Bio&Pharma (Lead Investor)
Proceeds Purpose
The company, which has secured a total of $50M in financing since launching in 2020, intends to use the financing for continued advancement of the clinical trial for SynKIR�-110, a first-in-class KIR-CAR T cell immunotherapy candidate for solid tumors, and pre-clinical development of SynKIR�-310, a KIR-CAR T cell immunotherapy therapeutic for blood cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3675 Market St 200
Philadelphia, PA 19104
USA
Philadelphia, PA 19104
USA
Phone
Website
Email Address
Overview
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bryan Kim
Chief Operating Officer
Calvin Rhee
Co-Founder
Donald Siegel
Browse more venture capital transactions:
Prev: 7/18/2023: Prospective venture capital transaction
Next: 7/18/2023: MUSINSA venture capital transaction
Share this article
News on VC Transactions
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs